- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02695823
Incidence of Intracranial Hypertension During Liver Transplantation Estimated by Non-invasive Ultrasound Methods. (TOH-HTIC)
Acute or chronic liver failure (fulminant hepatitis or advanced cirrhosis) disrupts brain physiology. Beyond classical hepatic encephalopathy, intracranial hypertension may occur.During liver transplantation (LT) surgery, many factors can lead to cerebral assault. In addition, intracranial hypertension measured with invasive methods has been described in certain phases of LT, especially at the time of reperfusion.
The invasive monitoring of the intracranial pressure is not used in these patients, due to a high risk of infection and bleeding. The non-invasive monitoring of intracranial pressure has been widely developed in recent years : transcranial doppler and recently ultrasound of the optic nerve sheath (ONSD) allow an effective detection of intracranial hypertension.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Lyon, France, 69004
- Département d'anesthésie réanimation
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients ≥ 18 years
- Patients who underwent orthotopic liver transplantation
- Patients who have received clear information and not opposed to participate in the study
- Patients affiliated to a social security scheme or similar
- Patients not undergoing a measure of legal protection
Exclusion Criteria:
- Opposition to participation in the study
- Patients < 18 years
- Pregnant women or breastfeeding
- Deprived of individual liberty
- Non-affiliated to a social security scheme
- Known ophthalmic pathology: untreated cataracts, glaucoma
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Patients undergoing liver transplantation
|
Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension. Search of any neurological complication during the 5 postoperative days. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Measure of the optic nerve sheath diameter during surgery.
Délai: at incision
|
A value of the optic nerve sheath diameter (averaged over 2 measures) greater than 5.7 mm will be considered pathological, indicating the strong likelihood of intracranial hypertension (PPV near 100% for an intracranial pressure > 25 cmh2o in the literature) The optic nerve sheath diameter will be measured by ultrasonography, in accordance with existing protocols: Use probe 7.5 Mhz in 2D mode, patient supine dorsi, implementation of ultrasound gel on the closed eyelid, search for the optimal window 3mm, optic nerve sheath diameter measurement behind the retina using an electronic cursor along an axis perpendicular to the optic nerve. 2 measurements per side (sagittal and transverse plane) averaged.
Values> 5.7mm are deemed pathological.
|
at incision
|
Measure of the optic nerve sheath diameter during surgery.
Délai: at anhepatic phase + 30 min
|
A value of the optic nerve sheath diameter (averaged over 2 measures) greater than 5.7 mm will be considered pathological, indicating the strong likelihood of intracranial hypertension (PPV near 100% for an intracranial pressure > 25 cmh2o in the literature) The optic nerve sheath diameter will be measured by ultrasonography, in accordance with existing protocols: Use probe 7.5 Mhz in 2D mode, patient supine dorsi, implementation of ultrasound gel on the closed eyelid, search for the optimal window 3mm, optic nerve sheath diameter measurement behind the retina using an electronic cursor along an axis perpendicular to the optic nerve. 2 measurements per side (sagittal and transverse plane) averaged.
Values> 5.7mm are deemed pathological.
|
at anhepatic phase + 30 min
|
Measure of the optic nerve sheath diameter during surgery.
Délai: at declamping + 5 min
|
A value of the optic nerve sheath diameter (averaged over 2 measures) greater than 5.7 mm will be considered pathological, indicating the strong likelihood of intracranial hypertension (PPV near 100% for an intracranial pressure > 25 cmh2o in the literature) The optic nerve sheath diameter will be measured by ultrasonography, in accordance with existing protocols: Use probe 7.5 Mhz in 2D mode, patient supine dorsi, implementation of ultrasound gel on the closed eyelid, search for the optimal window 3mm, optic nerve sheath diameter measurement behind the retina using an electronic cursor along an axis perpendicular to the optic nerve. 2 measurements per side (sagittal and transverse plane) averaged.
Values> 5.7mm are deemed pathological.
|
at declamping + 5 min
|
Measure of the optic nerve sheath diameter during surgery.
Délai: at declamping + 30 min
|
A value of the optic nerve sheath diameter (averaged over 2 measures) greater than 5.7 mm will be considered pathological, indicating the strong likelihood of intracranial hypertension (PPV near 100% for an intracranial pressure > 25 cmh2o in the literature) The optic nerve sheath diameter will be measured by ultrasonography, in accordance with existing protocols: Use probe 7.5 Mhz in 2D mode, patient supine dorsi, implementation of ultrasound gel on the closed eyelid, search for the optimal window 3mm, optic nerve sheath diameter measurement behind the retina using an electronic cursor along an axis perpendicular to the optic nerve. 2 measurements per side (sagittal and transverse plane) averaged.
Values> 5.7mm are deemed pathological.
|
at declamping + 30 min
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Measurement of intracranial hypertension with transcranial Doppler during surgery.
Délai: at incision
|
Diastolic velocity value of less than 20 cm s-1 and a pulsatility index greater than 1.4 will be considered pathological, indicating a high probability of intracranial hypertension. The transcranial Doppler measurements are performed according to the existing protocols: use of a cardiac probe 2 Mhz, positioned temporal window, the circle of Willis color Doppler tracking then collecting the Doppler signal of the middle cerebral artery in Doppler pulsed with the insonation angle as small as possible to a depth between 40 and 60 mm. Measuring systolic, diastolic and mean velocity )Vs, Vd, Vm) and calculating the pulsatility Index (PI) bilaterally. PI values of> 1.4 and Vd <20 cm s-1 will be considered pathological. |
at incision
|
Measurement of intracranial hypertension with transcranial Doppler during surgery.
Délai: at anhepatic phase + 30 min
|
Diastolic velocity value of less than 20 cm s-1 and a pulsatility index greater than 1.4 will be considered pathological, indicating a high probability of intracranial hypertension. The transcranial Doppler measurements are performed according to the existing protocols: use of a cardiac probe 2 Mhz, positioned temporal window, the circle of Willis color Doppler tracking then collecting the Doppler signal of the middle cerebral artery in Doppler pulsed with the insonation angle as small as possible to a depth between 40 and 60 mm. Measuring systolic, diastolic and mean velocity )Vs, Vd, Vm) and calculating the pulsatility Index (PI) bilaterally. PI values of> 1.4 and Vd <20 cm s-1 will be considered pathological. |
at anhepatic phase + 30 min
|
Measurement of intracranial hypertension with transcranial Doppler during surgery.
Délai: at declamping + 5 min
|
Diastolic velocity value of less than 20 cm s-1 and a pulsatility index greater than 1.4 will be considered pathological, indicating a high probability of intracranial hypertension. The transcranial Doppler measurements are performed according to the existing protocols: use of a cardiac probe 2 Mhz, positioned temporal window, the circle of Willis color Doppler tracking then collecting the Doppler signal of the middle cerebral artery in Doppler pulsed with the insonation angle as small as possible to a depth between 40 and 60 mm. Measuring systolic, diastolic and mean velocity )Vs, Vd, Vm) and calculating the pulsatility Index (PI) bilaterally. PI values of> 1.4 and Vd <20 cm s-1 will be considered pathological. |
at declamping + 5 min
|
Measurement of intracranial hypertension with transcranial Doppler during surgery.
Délai: at declamping + 30 min
|
Diastolic velocity value of less than 20 cm s-1 and a pulsatility index greater than 1.4 will be considered pathological, indicating a high probability of intracranial hypertension. The transcranial Doppler measurements are performed according to the existing protocols: use of a cardiac probe 2 Mhz, positioned temporal window, the circle of Willis color Doppler tracking then collecting the Doppler signal of the middle cerebral artery in Doppler pulsed with the insonation angle as small as possible to a depth between 40 and 60 mm. Measuring systolic, diastolic and mean velocity )Vs, Vd, Vm) and calculating the pulsatility Index (PI) bilaterally. PI values of> 1.4 and Vd <20 cm s-1 will be considered pathological. |
at declamping + 30 min
|
Measurement of intracranial hypertension with transcranial Doppler
Délai: at 1 day after surgery.
|
we use the same methods and the same thresholds as those used during surgery (primary outcome measure, and measure1 of secondary outcome measure)
|
at 1 day after surgery.
|
Measure of the optic nerve sheath diameter after surgery.
Délai: at 1 day after surgery.
|
we use the same methods and the same thresholds as those used during surgery (primary outcome measure, and measure1 of secondary outcome measure)
|
at 1 day after surgery.
|
Measurement of intracranial hypertension with transcranial Doppler
Délai: at 5 days after surgery.
|
we use the same methods and the same thresholds as those used during surgery (primary outcome measure, and measure1 of secondary outcome measure)
|
at 5 days after surgery.
|
Measure of the optic nerve sheath diameter after surgery.
Délai: at 5 days after surgery.
|
we use the same methods and the same thresholds as those used during surgery (primary outcome measure, and measure1 of secondary outcome measure)
|
at 5 days after surgery.
|
The early appearance of neurological complications after surgery.
Délai: During the 5 days following surgery
|
A monitoring with simultaneous collection of clinical, biological and ultrasound parameters, will be done.
Neurological complications after surgery will be defined by the presence of at least one of the following criteria: Glasgow score < 14 in a non-sedated patient, behavioral disorders, agitation (evaluation according to the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) score), epilepsy, imaging or MRI scan.
Pathological evolved compared to the preoperative including hemorrhagic or thrombotic cardiovascular event.
Various confounding factors will be considered (serum sodium, serum tacrolimus, serum magnesium, ammonia, sedatives).
|
During the 5 days following surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Mathieu GAZON, MD, Hospices Civils De Lyon
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 69HCL15_0483
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Transplantation hépatique
-
Abramson Cancer Center of the University of PennsylvaniaRetiréPatients cancéreux subissant une greffe de cellules souches (RCT of ACP for Transplant)
Essais cliniques sur Ultrasound
-
Medical Corps, Israel Defense ForceRecrutementBlessure traumatique | Plaie hémorragiqueIsraël
-
Academisch Medisch Centrum - Universiteit van Amsterdam...ComplétéVariabilité inter et intra-observateur des mesures Doppler de l'artère utérine au premier trimestre.Mesure Doppler de l'artère utérinePays-Bas
-
Seno Medical Instruments Inc.Complété
-
Federal University of São PauloBRICNET - Brazilian Research in Intensive Care NetworkPas encore de recrutementChoc septique | Patients gravement malades
-
Riverside University Health System Medical CenterInconnuePatients en état de choc et intubés dans la salle de traumatologie (TB)États-Unis
-
Innovative MedicalComplété
-
Helse Nord-Trøndelag HFNorwegian University of Science and Technology; St. Olavs HospitalComplétéAccident vasculaire cérébral | Accident ischémique transitoire | Attaque ischémique, transitoire | Accident vasculaire cérébral | Apoplexie cérébrovasculaireNorvège
-
Ajou University School of MedicineRésiliéSténose de l'artère coronaireCorée, République de
-
Connolly Hospital BlanchardstownRoyal College of Surgeons, Ireland; European Society for Trauma and Emergency... et autres collaborateursComplétéDiverticulite colique | Maladie biliaire | Calcul biliaire; Cholécystite aiguë | Abcès PelvienIrlande, Italie, Le Portugal, Espagne